AIM
ONCE

ARK Investment Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

ARK Investment Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-129
Closed -$5K – 201
2018
Q4 		$5K Hold
129
– – ﹤0.01% 193
2018
Q3 		$7K Buy
+129
New +$8.82K ﹤0.01% 202

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ARK Investment Management's ONCE Position: Q1 2019 in Review

ARK Investment Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2019, closing a stake of 129 shares — an estimated $5K sold.

ARK Investment Management first reported a position in ONCE in Q3 2018 and held it in 2 quarters. The position peaked at $7K in Q3 2018. 199 funds tracked by Wall St. Rank hold ONCE as of Q1 2019.

  • ARK Investment Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • ARK Investment Management sold 129 Spark Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $5K.
  • ARK Investment Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2018 and held it in 2 quarters.
  • ARK Investment Management's Spark Therapeutics, Inc. Common Stock position peaked at $7K in Q3 2018.
  • 199 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2019.

Based on ARK Investment Management's 13F filing for Q1 2019, filed 13 May 2019.